		HCQ vs SSZ	AZM vs AMX
Follow-up	Outcome	CalHR (95% CI) [I2]	
30-day	All-cause mortality	0.76 (0.44–1.32) [0.21]	1.36 (0.94–1.97) [<0.01]
	Myocardial infarction	1.15 (0.92–1.43) [<0.01]	− 1.07 (0.88−1.30) [<0.01]
	Cardiovascular events	1.01 (0.87–1.16) [<0.01]	
	Cardiac arrhythmia	0.90 (0.78–1.03) [<0.01]	
	Bradycardia	0.88 (0.66–1.16) [<0.01]	0.93 (0.70–1.25) [<0.01]
	Transient ischemic attack	1.17 (0.90–1.53) [<0.01]	— 1.01 (0.71–1.44) [0.2] —— <del>——————————————————————————————————</del>
	Stroke	1.16 (0.93–1.45) [<0.01]	− 1.11 (0.91−1.36) [<0.01]
	Venous thromboembolism	0.96 (0.81–1.13) [<0.01]	0.99 (0.83–1.18) [0.17]
	Gastrointestinal bleeding	1.09 (0.89–1.33) [<0.01]	1.02 (0.85–1.22) [0.03]
	Acute renal failure	1.03 (0.88–1.20) [<0.01]	
	End stage renal disease	1.07 (0.59–1.93) [0.11]	1.14 (0.76–1.69) [<0.01]
	Hepatic failure	0.67 (0.45–1.01) [<0.01]	0.88 (0.56–1.39) [<0.01]
	Acute pancreatitis	0.97 (0.72–1.30) [<0.01]	0.94 (0.69–1.27) [<0.01]
On-treatment	All-cause mortality		0.95 (0.83–1.08) [0.19]
	Myocardial infarction	1.11 (0.86–1.44) [<0.01]	-
	Cardiovascular events	1.02 (0.79–1.31) [<0.01]	1.01 (0.95–1.07) [0.29]
	Bradycardia	1.09 (0.84–1.42) [<0.01]	−
	Transient ischemic attack	1.04 (0.80–1.35) [<0.01]	- 1.02 (0.94–1.11) [<0.01]
	Stroke		0.99 (0.92–1.06) [<0.01]
	Venous thromboembolism	1.00 (0.77–1.30) [0.29]	1.06 (0.97–1.15) [0.28]
	Gastrointestinal bleeding		1.01 (0.93–1.10) [0.13]
	Acute renal failure	1.18 (0.91–1.52) [0.3]	— 0.98 (0.93–1.02) [<0.01] <
	End stage renal disease	1.23 (0.92–1.63) [<0.01]	── 0.93 (0.82–1.05) [<0.01]
	Hepatic failure	1.06 (0.79–1.42) [<0.01]	−
	Acute pancreatitis	0.99 (0.76–1.29) [<0.01]	1.02 (0.92–1.14) [<0.01]
		0.25 0.5 1 Favors HCQ CalHR	2 4 0.25 0.5 1 2 4 Favors SSZ Favors AZM CalHR Favors AMX